Benefits of Artificial Labor Induction Agents: A Survey among Healthcare Professionals

Introduction Artificial labor induction is increasingly common globally and in Morocco. However, disparities persist in the methods used and the training of professionals. Prostaglandins, particularly misoprostol and dinoprostone, are widely utilized, but their use raises concerns regarding effectiveness, safety, and pharmacovigilance.  Objectives: This study aims to evaluate the practices of healthcare professionals in the Rabat region, Morocco, regarding artificial labor induction, identify preferences for the agents used, and analyze their knowledge. It also seeks to optimize the use of artificial induction agents while ensuring effective and appropriate hospital management.  Materials and Methods: This is a prospective, descriptive, and analytical study conducted between November 2024 and January 2025 among gynecologists in the Rabat region. An exhaustive sampling included practitioners from both public and private sectors, as well as specialists in training. Data were collected using a validated questionnaire and analyzed with Microsoft Excel 2019.  Results: The study revealed that 92% of practitioners regularly use prostaglandins for labor induction. Among them, 56% prefer dinoprostone due to its safety profile, while misoprostol is favored for its effectiveness and cost. However, 72% of respondents had no specific training on these agents, and 76% do not systematically report adverse effects. These gaps contribute to heterogeneous practices and insufficient pharmacovigilance. A notable paradox was identified: although misoprostol is considered more effective, its use is associated with a higher risk of adverse effects, such as uterine hypertonia and fetal distress.  Conclusion: This study confirms the importance of adequate and continuous training for healthcare professionals on the use of artificial labor induction agents. The implementation of harmonized national protocols could reduce regional disparities, improve clinical practices, and enhance pharmacovigilance. Integrating these strategies into training programs and obstetric care pathways is crucial to optimizing maternal-fetal outcomes while ensuring maximum safety.